1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Hrabal, R.
Komives, E.A.
Ni, F.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
US
Protein Sci.
PRCIEI
0795
0961-8368
5
195
203
8745396
Structural resiliency of an EGF-like subdomain bound to its target protein, thrombin.
1996
10.2210/pdb1fgd/pdb
pdb_00001fgd
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
2018.180
THROMBOMODULIN
C-TERMINAL SUBDOMAIN, RESIDUES 409 - 426, OF 5TH EPIDERMAL GROWTH FACTOR (EGF)
1
man
polymer
no
no
CPEGYILDDGFICTDIDE
CPEGYILDDGFICTDIDE
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
sample
9606
Homo sapiens
database_2
pdbx_database_status
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
Other
1
0
1996-06-20
1
1
2008-03-24
1
2
2011-07-13
1
3
2022-02-23
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.process_site
Y
BNL
1995-11-28
REL
REL
11
BRUNGER
refinement
X-PLOR
3.1
CYS
409
n
1
CYS
409
A
PRO
410
n
2
PRO
410
A
GLU
411
n
3
GLU
411
A
GLY
412
n
4
GLY
412
A
TYR
413
n
5
TYR
413
A
ILE
414
n
6
ILE
414
A
LEU
415
n
7
LEU
415
A
ASP
416
n
8
ASP
416
A
ASP
417
n
9
ASP
417
A
GLY
418
n
10
GLY
418
A
PHE
419
n
11
PHE
419
A
ILE
420
n
12
ILE
420
A
CYS
421
n
13
CYS
421
A
THR
422
n
14
THR
422
A
ASP
423
n
15
ASP
423
A
ILE
424
n
16
ILE
424
A
ASP
425
n
17
ASP
425
A
GLU
426
n
18
GLU
426
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
ASP
416
A
N
ASP
8
A
O
ILE
420
A
O
ILE
12
1
A
ASP
417
56.80
-87.25
1
A
PHE
419
70.51
64.97
1
A
ILE
424
-174.78
-50.08
2
A
PHE
419
68.15
66.86
2
A
ASP
423
-63.32
-173.80
3
A
PRO
410
-75.68
-168.97
3
A
PHE
419
68.43
71.41
4
A
PHE
419
66.44
71.44
4
A
ASP
423
-68.57
-171.57
4
A
ILE
424
-115.84
-139.03
4
A
ASP
425
64.16
83.00
5
A
PHE
419
68.26
69.21
6
A
ASP
417
49.63
-94.79
6
A
PHE
419
72.42
69.50
6
A
ASP
423
-68.67
-172.92
7
A
PHE
419
66.89
70.07
8
A
PHE
419
61.05
60.64
8
A
ASP
423
-65.76
-172.52
9
A
ASP
417
54.94
-90.79
9
A
PHE
419
70.65
67.30
9
A
ILE
424
-121.38
-147.46
10
A
PRO
410
-77.14
-167.80
10
A
ASP
417
51.19
-96.65
10
A
PHE
419
70.84
70.90
10
A
ASP
423
-77.27
-162.56
11
A
ASP
416
-74.94
-169.45
11
A
ASP
423
-64.81
-171.75
model building
X-PLOR
3.1
refinement
X-PLOR
3.1
phasing
X-PLOR
3.1
EPIDERMAL GROWTH FACTOR (EGF) SUBDOMAIN OF HUMAN THROMBOMODULIN (NMR, 11 STRUCTURES)
1
Y
N
disulf
2.020
A
CYS
409
A
SG
CYS
1
1_555
A
CYS
421
A
SG
CYS
13
1_555
BLOOD COAGULATION INHIBITOR
BLOOD COAGULATION INHIBITOR, THROMBOMODULIN, EGF
TRBM_HUMAN
UNP
1
1
P07204
MLGVLVLGALALAGLGFPAPAEPQPGGSQCVEHDCFALYPGPATFLNASQICDGLRGHLMTVRSSVAADVISLLLNGDGG
VGRRRLWIGLQLPPGCGDPKRLGPLRGFQWVTGDNNTSYSRWARLDLNGAPLCGPLCVAVSAAEATVPSEPIWEEQQCEV
KADGFLCEFHFPATCRPLAVEPGAAAAAVSITYGTPFAARGADFQALPVGSSAAVAPLGLQLMCTAPPGAVQGHWAREAP
GAWDCSVENGGCEHACNAIPGAPRCQCPAGAALQADGRSCTASATQSCNDLCEHFCVPNPDQPGSYSCMCETGYRLAADQ
HRCEDVDDCILEPSPCPQRCVNTQGGFECHCYPNYDLVDGECVEPVDPCFRANCEYQCQPLNQTSYLCVCAEGFAPIPHE
PHRCQMFCNQTACPADCDPNTQASCECPEGYILDDGFICTDIDECENGGFCSGVCHNLPGTFECICGPDSALARHIGTDC
DSGKVDGGDSGSGEPPPSPTPGSTLTPPAVGLVHSGLLIGISIASLCLVVALLALLCHLRKKQGAARAKMEYKCAAPSKE
VVLQHVRTERTPQRL
427
444
1FGD
409
426
P07204
A
1
1
18
2
anti-parallel
A
LEU
415
A
LEU
7
A
ASP
416
A
ASP
8
A
ILE
420
A
ILE
12
A
CYS
421
A
CYS
13
1
P 1